Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist.

Corbin, A E; Pugsley, T A; Akunne, H C; Whetzel, S Z; Zoski, K T; Georgic, L M; Nelson, C B; Wright, J L; Wise, L D; Heffner, T G

Corbin, A E; Pugsley, T A; Akunne, H C; Whetzel, S Z; Zoski, K T; Georgic, L M; Nelson, C B; Wright, J L; Wise, L D; Heffner, T G.

Affiliation

Corbin AE; Psychiatric Disorders Therapeutics, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA.

Pharmacol Biochem Behav ; 59(2): 487-93, 1998 Feb.

Article in En | MEDLINE | ID: mdl-9476999

Subject(s)

Antipsychotic Agents/pharmacology; Benzimidazoles/pharmacology; Dopamine Antagonists/pharmacology; Dopamine D2 Receptor Antagonists; Piperidines/pharmacology; Animals; Biogenic Monoamines/biosynthesis; Brain Chemistry/drug effects; CHO Cells; Cholinergic Antagonists/pharmacology; Cricetinae; Dose-Response Relationship, Drug; Male; Mice; Motor Activity/drug effects; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Signal Transduction/drug effects; Thymidine/metabolism

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Piperidines / Antipsychotic Agents / Benzimidazoles / Dopamine Antagonists / Dopamine D2 Receptor Antagonists Limits: Animals Language: En Journal: Pharmacol Biochem Behav Year: 1998 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links